Clinical trials: Primary Cutaneous T-cell Lymphoma
Cutaneous T Cell Lymphoma, Mycosis Fungoides
A Phase 1, Open-label Study of the Absorption, Metabolism, Excretion of [14C]-Resminostat
Resminostat is a potent, orally available inhibitor of Class I, IIb and IV histone deacetylases (HDACs), including a pronounced activity against HDAC6.
- Conditions
- Cutaneous T Cell Lymphoma, Mycosis Fungoides, Sezary Syndrome
- Trial name
- NCT04955340
- Testing
- [14C]-resminostat
- Where
- United Kingdom
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- 4SC AG
Lymphoma
Chemotherapy and Photodynamic Therapy in Treating Patients With Cutaneous T-Cell Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Photodynamic therapy uses light and drugs that make cancer cells more sensitive to light to kill cancer…
- Trial name
- NCT00030589
- Testing
- bexarotene, methoxsalen, UV light therapy
- Where
- 19 sites in United States
- Sponsor
- Millennix
Cutaneous T-Cell Lymphoma
Study of IPH4102 in Patients With Relapsed/Refractory Cutaneous T-cell Lymphomas (CTCL)
The primary objective of this first in human study is to assess the safety and tolerability of increasing intravenous (IV) doses of single agent IPH4102 administered to patients with relapsed/refractory CTCL to characterize the…
- Trial name
- NCT02593045
- Testing
- IPH4102
- Where
- 5 sites in United States, France and 2 more
- Volunteers
- 44 people
- Sponsor
- Innate Pharma
Cutaneous T-Cell Lymphoma/Mycosis Fungoides
Study of WP1220 for the Treatment of Adult Subjects With Cutaneous T-Cell Lymphoma (CTCL)
Single center, pilot study to evaluate the safety and efficacy topical administration of WP1220 in subjects with Stage I, II or III Mycosis Fungoides (CTCL)
- Trial name
- NCT04702503
- Testing
- WP1220
- Where
- Poland
- Volunteers
- 5 people
- Sponsor
- Moleculin Biotech, Inc.
Mycosis Fungoides
Safety and Efficacy of Nitrogen Mustard in Treatment of Mycosis Fungoides
This study will evaluate the efficacy, tolerability and safety of the topical application of mechlorethamine (MCH) formulations in patients with stage I or IIA mycosis fungoides (MF).
- Trial name
- NCT00168064
- Testing
- mechlorethamine-MCH (nitrogen mustard)
- Where
- 12 sites in United States
- Volunteers
- 260 people
- Sponsor
- Yaupon Therapeutics
Lymphoma, T-Cell, Cutaneous, Mycosis Fungoides
Study of ONTAK (Denileukin Diftitox) in Previously Treated Cutaneous T-Cell Lymphoma Patients
The purpose of this study is to provide an opportunity for patients who exhibit progressive disease while receiving placebo on the companion 93-04-11 study to receive ONTAK.
- Conditions
- Lymphoma, T-Cell, Cutaneous, Mycosis Fungoides, Sezary Syndrome
- Trial name
- NCT00051012
- Testing
- ONTAK
- Where
- 34 sites in United States, Australia and 7 more
- Volunteers
- 86 people
- Sponsor
- Eisai Inc.
Cutaneous T-cell Lymphoma
Study of Pralatrexate in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma
This study is being conducted to identify how much and how often pralatrexate, given with vitamin B12 and folic acid, can be given safely to patients with cutaneous T-cell lymphoma (CTCL) that has relapsed (returned after…
- Trial name
- NCT00554827
- Testing
- Vitamin B12, Folic Acid, Pralatrexate
- Where
- 10 sites in United States
- Volunteers
- 55 people
- Sponsor
- Acrotech Biopharma Inc.
Cutaneous T-cell Lymphoma
A Single Agent Phase II Study of Romidepsin (Depsipeptide, FK228) in the Treatment of Cutaneous T-cell Lymphoma (CTCL)
GPI-04-0001 was a Phase II, non-randomized, open label, single arm study that was conducted at approximately 30 sites, primarily in the United States, Europe and Russia.
- Trial name
- NCT00106431
- Testing
- romidepsin (depsipeptide, FK228)
- Where
- 11 sites in United States, France and 4 more
- Volunteers
- 102 people
- Sponsor
- Celgene
T Cell Lymphoma
HuMax-CD4 in Non-Cutaneous T-Cell Lymphoma
The purpose of this study is to assess the safety and efficacy of treatment of non-cutaneous T-cell lymphoma with treatment with CD4.
- Trial name
- NCT00877656
- Testing
- HuMax-CD4
- Volunteers
- 21 people
- Sponsor
- Emergent BioSolutions
Advanced Solid Tumor, Cutaneous T-cell Lymphoma (CTCL)
A Phase I Trial of SIM1811-03 in Subjects With Advanced Solid Tumors and Cutaneous T-cell Lymphoma
This is a first in human, open-label, dose escalation and expansion Phase 1 study of SIM1811-03 in adult patients with advanced solid tumors and cutaneous T-cell lymphoma.
- Trial name
- NCT05569057
- Testing
- SIM1811-03
- Where
- 6 sites in United States
- Volunteers
- 100 people
- Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
Relapsed or Refractory Peripheral T-cell Lymphoma(PTCL),Cutaneous T-cell Lymphoma(CTCL),Adult T-cell Leukemia/Lymphoma(ATLL)
A Phase I/II Study of ASTX660 in Patients With Relapsed or Refractory T-cell Lymphoma
Phase 1 (dose-escalation part): Investigate the tolerability and safety of ASTX660 in patients with r/r PTCL and r/r CTCL and determine the recommended dose (RD) for the Phase 2.
- Trial name
- NCT04362007
- Testing
- ASTX660
- Where
- Japan
- Volunteers
- 8 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Lymphoma, T-cell, Peripheral, Lymphoma, T-cell, Cutaneous
A Study of Remitoro in Participants With Recurrent or Refractory Peripheral T Cell Lymphoma and Cutaneous T Cell Lymphoma (All Case Study)
The primary purpose of the study is to investigate the incidence of adverse drug reactions (ADRs) (ADR of special interest: capillary leak syndrome, infusion reaction, rhabdomyolysis, myelosuppression, infection, hepatic…
- Trial name
- NCT05137847
- Testing
- Remitoro
- Where
- 3 sites in Japan
- Volunteers
- 118 people
- Sponsor
- Eisai Inc.
Disease, Hodgkin, Lymphoma, Large-Cell, Anaplastic
A Treatment-Option Protocol to Provide Brentuximab Vedotin to Eligible Patients Completing Studies SGN35-005 or C25001
The purpose of this study is to provide the option of brentuximab vedotin treatment to eligible patients in studies SGN35-005 and C25001
- Conditions
- Disease, Hodgkin, Lymphoma, Large-Cell, Anaplastic, Lymphoma, Non-Hodgkin, Lymphoma, T-Cell, Cutaneous
- Trial name
- NCT01196208
- Testing
- brentuximab vedotin
- Where
- 31 sites in United States, Australia and 13 more
- Sponsor
- Seagen Inc.
Cancer
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
This is a phase III, randomized, double-blind, placebo-controlled, multicenter study of the clinical response to fentanyl sublingual spray as a treatment for breakthrough cancer pain.
- Trial name
- NCT00538850
- Testing
- Fentanyl sublingual spray
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- INSYS Therapeutics Inc
Cutaneous T-Cell Lymphoma
A Study for Participants With Relapsed Cutaneous T-Cell Lymphoma
The purpose of the study is to determine the efficacy and safety of enzastaurin in participants with Cutaneous T-Cell Lymphoma (CTCL) who failed prior therapies.
- Trial name
- NCT00744991
- Testing
- Enzastaurin
- Where
- 16 sites in United States
- Volunteers
- 25 people
- Sponsor
- Eli Lilly and Company
LGLL - Large Granular Lymphocytic Leukemia, Primary Cutaneous Gamma-Delta T-Cell Lymphoma
A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
This is a multicenter, first-in-human, Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor activity of DR-01 in adult patients with large granular lymphocytic leukemia or…
- Conditions
- LGLL - Large Granular Lymphocytic Leukemia, Primary Cutaneous Gamma-Delta T-Cell Lymphoma, Primary Cutaneous CD8+ Aggressive Epidermotropic T-Cell Lymphoma, Hepatosplenic T-cell Lymphoma
- Trial name
- NCT05475925
- Testing
- DR-01
- Where
- 37 sites in United States, Australia and 7 more
- Volunteers
- 200 people
- Sponsor
- Dren Bio
Lymphoma
A Study of TLN-254 in Participants With Relapsed or Refractory T-cell Lymphoma
The primary purpose of this study is to evaluate the anti-tumor activity of TLN-254 monotherapy in participants with relapsed or refractory T-cell lymphoma.
- Trial name
- NCT06733441
- Testing
- TLN-254
- Where
- 5 sites in United States, Canada
- Volunteers
- 50 people
- Sponsor
- Treeline Biosciences, Inc.
Persistent or Recurrent Cutaneous T-Cell Lymphoma
A Trial of E7777 in Persistent and Recurrent Cutaneous T-Cell Lymphoma
The purpose of this trial is to assess the efficacy of E7777 in participants with recurrent or persistent Cutaneous T-Cell Lymphoma (CTCL) in Stage I - III participants as assessed by objective response rate (ORR).
- Trial name
- NCT01871727
- Testing
- E7777 9 mcg/kg
- Where
- 22 sites in United States, Australia and 1 more
- Volunteers
- 112 people
- Sponsor
- Eisai Inc.
Mycosis Fungoides
Clinical Study Assessing Outcomes, Adverse Events, Treatment Patterns, and Quality of Life in Patients Diagnosed With Mycosis Fungoides Cutaneous T-cell Lymphoma
The Valchlor PROVe study is a multi-center, prospective, observational, US-based drug study that longitudinally follows patients with Mycosis Fungoides Cutaneous T-cell Lymphoma (MF-CTCL) who are receiving therapy with Valchlor.
- Trial name
- PROVe (NCT02296164)
- Testing
- Valchlor
- Where
- 36 sites in United States
- Volunteers
- 300 people
- Sponsor
- Helsinn Therapeutics (U.S.), Inc
T-Cell Lymphoma
A Study in Adults With Cutaneous T-cell Lymphoma (CTCL) Retreated With Brentuximab Vedotin
The main aim of this study is to describe how effective and safe the re-treatment of adults with cutaneous T-cell lymphoma (CTCL) with brentuximab vedotin is.
- Trial name
- NCT05886478
- Testing
- No intervention
- Where
- 11 sites in France, Germany and 2 more
- Volunteers
- 26 people
- Sponsor
- Takeda